Tobacco smoking and COVID-19: an old enemy in a new guise. Review of current publications
The review summarizes the current data on the relationship of tobacco smoking, e-cigarette use and the novel coronavirus infection COVID-19. The socio-demographic characteristics of patients with COVID-19 and associated diseases, which indicate a possible relationship between smoking and the disease, are analyzed. Recent large meta-analyzes demonstrating the increased risk of progression, the development of severe complications and adverse outcomes of COVID-19 in smokers, as well as in patients with chronic obstructive pulmonary disease, for which smoking is a leading risk factor, are shown. It is believed that tobacco smoking and e-cigarette use causes dose-dependent activation of the angiotensin-converting enzyme-2 receptor, by which virus penetrates to host cell. This may explain the higher risk of complicated COVID-19 in smokers and vapers. There is conflicting data because some studies showed some relatively low smoking prevalence among patients with COVID-19 compared with general population. This, in particular, was associated with poor-quality data collection about smoking, but, nevertheless, was the basis for hypotheses about the protective effect of nicotine against COVID-19. This issue needs further large independent studies, but it is clear so far that smoking is associated with the progression and adverse outcomes of COVID-19..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Кардиоваскулярная терапия и профилактика - 19(2020), 3 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
M. G. Gambaryan [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
вейпы |
|---|
| doi: |
10.15829/1728-8800-2020-2604 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ02932534X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ02932534X | ||
| 003 | DE-627 | ||
| 005 | 20230410104655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2020 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.15829/1728-8800-2020-2604 |2 doi | |
| 035 | |a (DE-627)DOAJ02932534X | ||
| 035 | |a (DE-599)DOAJ8531bd752b874485a774b3e944de8861 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RC666-701 | |
| 100 | 0 | |a M. G. Gambaryan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tobacco smoking and COVID-19: an old enemy in a new guise. Review of current publications |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The review summarizes the current data on the relationship of tobacco smoking, e-cigarette use and the novel coronavirus infection COVID-19. The socio-demographic characteristics of patients with COVID-19 and associated diseases, which indicate a possible relationship between smoking and the disease, are analyzed. Recent large meta-analyzes demonstrating the increased risk of progression, the development of severe complications and adverse outcomes of COVID-19 in smokers, as well as in patients with chronic obstructive pulmonary disease, for which smoking is a leading risk factor, are shown. It is believed that tobacco smoking and e-cigarette use causes dose-dependent activation of the angiotensin-converting enzyme-2 receptor, by which virus penetrates to host cell. This may explain the higher risk of complicated COVID-19 in smokers and vapers. There is conflicting data because some studies showed some relatively low smoking prevalence among patients with COVID-19 compared with general population. This, in particular, was associated with poor-quality data collection about smoking, but, nevertheless, was the basis for hypotheses about the protective effect of nicotine against COVID-19. This issue needs further large independent studies, but it is clear so far that smoking is associated with the progression and adverse outcomes of COVID-19. | ||
| 650 | 4 | |a курение | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a коронавирусная инфекция | |
| 650 | 4 | |a курение табака | |
| 650 | 4 | |a потребление электронных сигарет | |
| 650 | 4 | |a вейпы | |
| 653 | 0 | |a Diseases of the circulatory (Cardiovascular) system | |
| 700 | 0 | |a O. M. Drapkina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Кардиоваскулярная терапия и профилактика |d «SILICEA-POLIGRAF» LLC, 2019 |g 19(2020), 3 |w (DE-627)DOAJ000143863 |x 26190125 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2020 |g number:3 |
| 856 | 4 | 0 | |u https://doi.org/10.15829/1728-8800-2020-2604 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/8531bd752b874485a774b3e944de8861 |z kostenfrei |
| 856 | 4 | 0 | |u https://cardiovascular.elpub.ru/jour/article/view/2604 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1728-8800 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2619-0125 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2020 |e 3 | ||